PMID- 21573507
OWN - NLM
STAT- MEDLINE
DCOM- 20111103
LR  - 20181201
IS  - 1791-2431 (Electronic)
IS  - 1021-335X (Linking)
VI  - 26
IP  - 2
DP  - 2011 Aug
TI  - Clinical relevance of epidermal growth factor receptor (EGFR) alterations in 
      human pancreatic tumors.
PG  - 315-20
LID - 10.3892/or.2011.1309 [doi]
AB  - Pancreatic cancer is a malignant neoplasm with an extremely poor prognosis. The 
      mechanisms of aggressive growth and metastasis are currently not well understood. 
      Expression of epidermal growth factor receptor (EGFR) has been suggested to be 
      associated with the malignant transformation of pancreatic cancer. In this study, 
      we examined the EGFR status of 52 pancreatic tumors by PCR-sequencing (exons 19 
      and 21), immunohistochemistry and FISH probes. We subsequently investigated the 
      relationship between EGFR status and clinicopathological factors. Somatic 
      alterations in EGFR (R841R, T571T and R831C) were observed only in ductal 
      adenocarcinoma (3/34). In 4 (8%) of the 52 tumors analyzed EGFR was 
      overexpressed, 6 (12%) of the tumors showed moderate expression while 19 (32%) 
      were weakly stained. EGFR overexpression (3+ score) was frequently found in 
      endocrine tumors (29%) followed of ampullary tumors (13%; p < 0.01). No 
      significant correlation was observed between the presence of a somatic EGFR 
      mutation and clinicopathological variables. Fluorescence in situ hybridization 
      (FISH) analysis did not demonstrate amplification in any tumors. Only three 
      somatic mutations in the EGFR gene were detected in pancreatic ductal 
      adenocarcinoma and no association was observed with the clinical variables. Our 
      results suggest that EGFR mutations are rare in pancreatic tumors and not 
      associated with clinical prognosis, and treatment response.
FAU - Lozano-Leon, Antonio
AU  - Lozano-Leon A
AD  - Department of Gastroenterology and Foundation for Research in Digestive Diseases, 
      University Hospital Santiago de Compostela, c/ Choupana s/n. Santiago de 
      Compostela, Spain. antoniolozan@gmail.com
FAU - Perez-Quintela, Begona Vieites
AU  - Perez-Quintela BV
FAU - Iglesias-Garcia, Julio
AU  - Iglesias-Garcia J
FAU - Urisarri-Ruiz, Adela
AU  - Urisarri-Ruiz A
FAU - Larino-Noia, Jose
AU  - Larino-Noia J
FAU - Abdulkader, Ihab
AU  - Abdulkader I
FAU - Varo, Evaristo
AU  - Varo E
FAU - Forteza, Jeronimo
AU  - Forteza J
FAU - Dominguez-Munoz, J Enrique
AU  - Dominguez-Munoz JE
LA  - eng
PT  - Journal Article
DEP - 20110513
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Base Sequence
MH  - ErbB Receptors/biosynthesis/genetics/*metabolism
MH  - Female
MH  - Genetic Variation
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Molecular Sequence Data
MH  - Neoplasm Invasiveness
MH  - Neoplasm Staging
MH  - Pancreatic Neoplasms/genetics/*metabolism/*pathology
MH  - Polymerase Chain Reaction
MH  - Prognosis
MH  - Sequence Analysis, DNA
EDAT- 2011/05/17 06:00
MHDA- 2011/11/04 06:00
CRDT- 2011/05/17 06:00
PHST- 2010/11/05 00:00 [received]
PHST- 2010/12/30 00:00 [accepted]
PHST- 2011/05/17 06:00 [entrez]
PHST- 2011/05/17 06:00 [pubmed]
PHST- 2011/11/04 06:00 [medline]
AID - 10.3892/or.2011.1309 [doi]
PST - ppublish
SO  - Oncol Rep. 2011 Aug;26(2):315-20. doi: 10.3892/or.2011.1309. Epub 2011 May 13.